Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is APR-1051, which is in Phase 1 clinical trial for treatment of advanced solid tumors with biomarkers that may predict sensitivity to WEE1 inhibition. Its pipeline includes the ATRN-119, an ATR inhibitor that is in a Phase 1/2a clinical trials for treating advanced solid tumors having at least one mutation in a defined panel of DDR-related genes. It also includes an early-stage program, which is in lead optimization stage for an undisclosed DNA-damage response (“DDR”) target. The company is headquartered in Doylestown, Pennsylvania.